Effective Management of Dry Eye Disease in Saudi Arabia

Introduction to Dry Eye Disease and Treatment Options

Dry eye disease (DED) is a prevalent condition characterized by a loss of homeostasis of the tear film, leading to ocular symptoms and damage to the ocular surface. It is classified into two main categories: aqueous deficient dry eye (ADDE) and evaporative dry eye (EDE). ADDE is primarily attributed to inadequate tear production, whereas EDE involves excessive tear evaporation due to a compromised lipid layer. In Saudi Arabia, where extreme temperatures and low humidity are common, the incidence of DED is notably high, necessitating effective management strategies (AlShammeri et al., 2024).

The primary treatment approach for DED focuses on the use of tear supplements aimed at alleviating symptoms, enhancing tear film stability, and protecting the ocular surface. Among these, lipid-based and non-lipid-based tear supplements have gained popularity due to their distinct mechanisms of action. Lipid-based formulations, such as Cationorm® (CTN), are designed to enhance the lipid layer’s stability, thereby reducing tear evaporation. Non-lipid-based options, like Artelac Advanced® (0.2% sodium hyaluronate), rely on the hydrating properties of hyaluronic acid to improve tear film quality and comfort (AlShammeri et al., 2024).

Comparison of Lipid-Based and Non-Lipid-Based Tear Supplements

In managing DED, the choice between lipid-based and non-lipid-based eye drops is critical. Lipid-based supplements like Cationorm® contain mineral oils and emulsifiers that create a protective barrier, preventing rapid tear evaporation and enhancing comfort. These formulations are particularly beneficial in environments with low humidity, such as those prevalent in Saudi Arabia (AlShammeri et al., 2024).

On the other hand, non-lipid-based supplements, such as Artelac Advanced®, primarily utilize sodium hyaluronate to retain moisture and provide lubrication. Sodium hyaluronate is a naturally occurring polysaccharide in the tear film known for its high water-binding capacity, which enhances tear viscosity and stability, thus providing symptomatic relief for patients suffering from dry eye (AlShammeri et al., 2024).

Table 1: Composition of Tear Supplements

Clinical Efficacy of Cationorm® vs. Artelac Advanced®

Recent studies, such as the Twaiq Mountain Eye Study II, have investigated the clinical efficacy of lipid-based versus non-lipid-based tear supplements in patients with DED. The study involved 44 patients and assessed several parameters, including ocular surface symptoms, tear meniscus height (TMH), non-invasive tear break-up time (NITBUT), and corneal and conjunctival redness (AlShammeri et al., 2024).

The findings indicated that patients using Cationorm® experienced a significant reduction in dry eye symptoms, with the Ocular Surface Disease Index (OSDI) scores decreasing from 38.60 ± 23.13 at baseline to 14.25 ± 12.70 after four weeks of treatment. In contrast, Artelac Advanced® did not produce a similar decrease in symptom scores over the same period. Both treatments improved TMH, but the improvement was statistically significant in the Cationorm® group compared to the Artelac Advanced® group (P = 0.003) (AlShammeri et al., 2024).

Table 2: Clinical Outcomes at 4 Weeks

Impact on Tear Film Stability and Ocular Surface Health

Both lipid-based and non-lipid-based eye drops were effective in improving tear film stability and ocular surface health. However, Cationorm® demonstrated a superior ability to decrease ocular surface inflammation, as evidenced by the reduction in corneal and conjunctival redness scores. After four weeks of treatment, both groups showed significant improvements, indicating that regular use of these supplements can effectively manage the symptoms of DED and enhance overall ocular surface health (AlShammeri et al., 2024).

Safety Profile and Adverse Effects of Tear Supplements

The safety of both formulations was assessed by monitoring adverse effects during the study. No significant adverse events were reported in either treatment group, highlighting the tolerability of both Cationorm® and Artelac Advanced®. This is particularly important for patients who may require long-term therapy for DED, as the use of preservative-free formulations minimizes the risk of ocular irritation and toxicity (AlShammeri et al., 2024).

Conclusion and Recommendations for Future Research

In conclusion, both lipid-based (Cationorm®) and non-lipid-based (Artelac Advanced®) tear supplements effectively improved tear volume, tear film stability, and ocular surface health among patients suffering from dry eye disease in Saudi Arabia. However, lipid-based Cationorm® was particularly effective in reducing dry eye symptoms compared to Artelac Advanced®.

Future research should focus on larger multicenter trials to further evaluate the long-term efficacy and safety of these treatments. Additionally, exploring new formulations and combinations of existing treatments may enhance therapeutic outcomes for patients with dry eye disease.

FAQ Section

What is dry eye disease? Dry eye disease is a multifactorial condition characterized by a loss of homeostasis of the tear film, resulting in ocular symptoms such as dryness, irritation, and discomfort.

What are the main types of dry eye disease? The two primary types are aqueous deficient dry eye (ADDE) and evaporative dry eye (EDE). ADDE is caused by insufficient tear production, while EDE occurs due to excessive tear evaporation.

How do lipid-based and non-lipid-based tear supplements differ? Lipid-based supplements, like Cationorm®, stabilize the lipid layer of the tear film to reduce evaporation, while non-lipid-based supplements, such as Artelac Advanced®, use sodium hyaluronate to enhance moisture and lubrication.

Are there any side effects associated with tear supplements? Both Cationorm® and Artelac Advanced® are generally well-tolerated, with minimal to no reported adverse effects, making them safe options for managing dry eye disease.

What should I do if I experience dry eye symptoms? Consult an eye care professional for an evaluation and discuss appropriate treatment options, which may include the use of tear supplements.

References

1. AlShammeri, S., AlKhaldi, S. A., AlMutairi, R. T., AlZamil, H. A., AlJohani, S. M., AlJohani, S., & AlDakhil, S. (2024). Therapeutic efficacy of two tear supplements in the management of dry eye disease in Saudi Arabia: The Twaiq Mountain Eye Study II. Saudi Journal of Ophthalmology, 39(2), 123-130

2. Kasai, S., Ukai, S., Kuroda, J., Yamauchi, T., Yamada, D., Saitoh, A., Iriyama, S., Suzuki, M., & Yoshizawa, K. (2025). Pain-stimulated ultrasound vocalizations and their impact on pain response in mice. PLOS ONE, 32(4), e0324730. https://doi.org/10.1371/journal.pone.0324730

3. Mishra, S. K., & Saito, A. (2025). Target identification of natural products in cancer with chemical proteomics and artificial intelligence approaches. Cancer Biology & Medicine, 22(1), 123-134. https://doi.org/10.20892/j.issn.2095-3941.2025.0145